Obesity

The FDA Endocrinologic and Metabolic Drugs Advisory Committee voted overwhelmingly (20 to 2) in favor of approving the obesity drug Qnexa (Vivus, Inc.), a combination of phentermine and controlled-release topiramate. Qnexa could be the first prescription drug for obesity to reach the market since 1999.…

An FDA advisory committee’s endorsement of the anti-obesity drug Qnexa could re-energize the pharmaceutical industry after several years of disappointment in trying to develop anti-obesity drugs.…

Researchers at Washington University School of Medicine in St. Louis have identified a potent regulator of sensitivity to insulin….

Vivus Inc said the FDA has asked the company to remove a contraindication in the proposed label of its obesity drug Qnexa, a move that could help it reach a broader patient population.…

The study findings indicate that medical professionals with normal BMI more frequently reported discussing weight loss with patients than overweight or obese medical professionals….

Little changed in U.S. obesity rates in recent years, but we cannot let down in providing information and programs….

Excess calories, not mix of protein, fat, or carbohydrate, key in causing obesity.…

Childhood growth patterns, childhood obesity, maternal body mass index (BMI), and father’s employment are probable early markers for adult obesity.…

Medicare will pick up the tab for obesity screening and intensive behavioral counseling, the Centers for Medicare and Medicaid announced this week.…

A new report uncovered an overall wage differential between those of normal weight and those who are obese, especially when it comes to women. The research, demonstrates the impact obesity may have on a person’s paycheck.…